Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 27,848 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo and sham treatment Clear all

Conditions: Fatigue
Interventions: Alpinia galanga formulation, Theacrine formulation, Caffeine formulation, Placebo; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Stroke, CVA
Interventions: Beetroot Juice supplement, Placebo supplement; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Social Discrimination, Sexual and Gender Minorities, Mindfulness
Interventions: Introduction Only, Purpose Only, Connection Only, Connection and Purpose, Awareness Only, Awareness and Purpose, Awareness, Purpose, and Connection, Awareness and Connection; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Prostate Cancer
Interventions: Flutamide, Placebo; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acne Rosacea
Interventions: Topical Powder, Placebo Topical Powder; Drug
Lead sponsor: Dermata Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions: Ketamine, TAK-063, TAK-063 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Ulcerative Colitis (UC)
Interventions: ONO-6414, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: LX4211 400 mg, LX4211 800 mg, LX4211 Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dermatomyositis
Interventions: GLPG3667, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Scottsdale, Arizona • Upland, California • Kendall, Florida + 5 more

Conditions: Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
Interventions: TNX-102 SL, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 29
States / cities: Birmingham, Alabama • Oceanside, California • Santa Ana, California + 25 more

Conditions: Coarctation of Aorta, High Blood Pressure
Interventions: Losartan, Amlodipine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: ACT-1004-1239, Placebo, ACT-1004-1239 (Food-effect subpart), Placebo (Food-effect subpart); Drug · Other
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma, Dental Caries
Interventions: Chinese Licorice Root; Dietary Supplement
Lead sponsor: University of Nebraska; Other
Eligibility: 4 Years to 16 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Asthma
Interventions: Dexamethasone, placebo; Drug
Lead sponsor: Geoffrey W Jara-Almonte; Other
Eligibility: 18 Months to 20 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions: Oregovomab, Paclitaxel, Carboplatin, Placebo; Biological · Drug
Lead sponsor: CanariaBio Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more

Conditions: Herpes Zoster, Vaccine-Preventable Diseases
Interventions: Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo; Biological · Drug
Lead sponsor: Beijing Luzhu Biotechnology Co., Ltd.; Other
Eligibility: 50 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Parkinson Disease
Interventions: INS-GSH, Matched Placebos; Drug
Lead sponsor: Gateway Institute for Brain Research; Industry
Eligibility: 30 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more

Conditions: Myelodysplastic Syndrome
Interventions: Siltuximab, Placebo, Best supportive care (BSC); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Tampa, Florida • Boston, Massachusetts • New York, New York + 2 more

Conditions: Migraine
Interventions: Erenumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 59
States / cities: Phoenix, Arizona • Anaheim, California • Encino, California + 55 more

Conditions: Cannabidiol, Drug Induced Liver Injury, Drug Interaction
Interventions: Cannabidiol, Placebo, Citalopram, Morphine; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 55 Years
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Depressive Disorder
Interventions: WellbutrinXL, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetic Retinopathy
Interventions: Runcaciguat (BAY1101042), Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Modesto, California • Lakeland, Florida • Pinellas Park, Florida + 6 more

Conditions: Coronary Artery Disease
Interventions: Rosuvastatin, Colchicine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health

Acute Effects of Beetroot Juice on Locomotor Economy and Capacity in Chronic Stroke

Reducing Daily Stress Among Sexual and Gender Minorities

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

DMT310-005 Topical in the Treatment of Acne Rosacea

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Herbal Lollipops on Oral Bacterial Levels and DMFT/Dmft Scores of Children With Asthma Using Inhalers

Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine